Why Alnylam’s Best Quarter Ever Didn’t Come With a Richer Valuation

2026 has marked a important turning constituent successful biotech superior markets, not conscionable a tiny comeback. Venture backing for biotech startups reached $9.1 cardinal successful the archetypal fractional of the year, the highest first-half full since 2022, portion 13 biotech IPOs raised a combined $4.5 billion, with a median haul of astir $302 cardinal per offering, unusually precocious by caller standards, with the bulk of this year's debutants inactive trading supra their offering price. Dealmaking has besides maintained its pace, with 38 acquisitions closing successful the aforesaid clip period, placing the manufacture astatine its fastest M&A gait successful astatine slightest 7 years.

Underneath that wide comeback is simply a much unsocial validation communicative for RNA interference successful particular. The marketplace for RNAi treatments is expected to emergence from $2.9 cardinal successful 2025 to $3.6 cardinal successful 2026. This maturation comes aft RNAi spent astir 2 decades arsenic a probe curiosity earlier receiving its archetypal licensed medicine successful 2018. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) has precocious emerged arsenic the clearest illustration of this transition, and the market's absorption raises the question of whether the communicative has been decently priced.

The Quarter Itself

During Q1 2026, Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) exceeded $1 cardinal successful quarterly merchandise gross for the archetypal clip successful its history, with $1.036 cardinal successful nett merchandise revenue, up 121% year-over-year and 4% sequentially implicit Q4 2025, connected full gross of $1.17 billion, up 96% year-over-year. AMVUTTRA unsocial delivered $890 million, bringing full TTR franchise gross (AMVUTTRA positive ONPATTRO) to $910 million, up 153% from the erstwhile year.

That maturation wholly flipped the company's bottommost line: GAAP nett income was $206 million, compared to a $15.9 cardinal nonaccomplishment successful the aforesaid 4th the erstwhile year, and GAAP income from operations came successful astatine $268.6 million, up from a prior-year loss. A institution that continued to pain currency a twelvemonth agone is present solidly profitable connected a GAAP basis.

The Growth Looks Durable, Not Front-loaded

The maturation is besides not driven by a azygous medicine, which is important for semipermanent viability. The uncommon illness franchise, GIVLAARI and OXLUMO, added $126 million, expanding 15% year-over-year, portion AMVUTTRA's worldwide rollout has reached 7 markets, with outgo negotiations inactive ongoing successful the Spanish and French markets. This means that a important information of the gross basal is yet to beryllium released.

Patient retention information confirms that the maturation is sustained alternatively than sudden. Real-world adherence to vutrisiran has remained supra 90% implicit the past 2 years, and the institution has gained implicit 1,200 further AMVUTTRA prescribers since its cardiomyopathy motorboat a twelvemonth ago.